eqracer think back as a investment what did you invest per share in PCYC ? Now we are getting all this cash plus 4 shares of ABBV each share has a Dividend Yield of 4.1% cash per share Quarterly Dividend 4.1% to $0.51 I think its very good deal IMO.Best of luck my friend.
Truth be told Patience ,accumulate and this is a winner IMHO .ICML Meeting (Lugano):
Date/Time: Wednesday, June 17, 2015, 17:45 CEST
Abstract Number: 038 (Oral Presentation)
Presentation Title: TGR-1202, A NOVEL ONCE DAILY PI3K δ INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY IN PATIENTS WITH CLL AND B-CELL LYMPHOMA
Presenter: Owen A. O'Connor, MD, PhD, Columbia Presbyterian Lymphoma Center, New York, NY
Date/Time: Thursday, June 18, 2015, 17:15 CEST
Abstract Number: 105 (Oral Presentation)
Presentation Title: UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB ACHIEVES 95% ORR IN PATIENTS WITH HIGHRISK RELAPSED/REFRACTORY CLL
Presenter: John Burke, MD, Rocky Mountain Cancer Center/US Oncology, Aurora, CO
Date/Time: Thursday, June 18, 2015, 17:25 CEST
Abstract Number: 106 (Oral Presentation)
Presentation Title: THE CHEMOTHERAPY-FREE TRIPLET OF UBLITUXIMAB, TGR-1202, AND IBRUTINIB IS SAFE AND HIGHLY ACTIVE IN RELAPSED B-CELL MALIGNANCIES
Presenter: Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX
Date/Time: Thursday, June 18, 2015
Abstract Number: 284 (Poster)
Presentation Title: UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL
Presenter: Matthew Lunning, DO, University of Nebraska, Omaha, NE
Remember PCYC with J&J well this is good also...Nomura Holdings analyst Ian Somaiya shaved a dollar off his price target for Celgene — now 146 — due to the upfront costs. However, he was generally positive on the deal, saying the potential drug launches suggest upside to Celgene's long-term guidance of $20 billion in revenue in 2020."We believe the deal provides Celgene with significant optionality and represents another example of the company using its balance sheet to gain access to a potentially best-in-class development platform," Somaiya wrote in his note.
Leerink Partners' Howard Liang also liked the deal, adding that this also explained Celgene's recent restructuring of its partnership with Bluebird Bio (NASDAQ:BLUE). In 2013, Celgene made a deal with Bluebird giving it the option to pursue Bluebird's preclinical CAR-T candidates. On June 3, Celgene announced that it had decided to focus on products using B cell maturation antigen (BCMA) technology and leave the rest to Bluebird. The Juno deal specifically excluded Juno's BCMA program, so the two collaborations don't conflict.